SOURCE: BioNeutral Group, Inc.

January 21, 2014 07:45 ET

BioNeutral Announces U.S. Sales & Distribution Agreement With Quip Laboratories, Inc.

NEWARK, NJ--(Marketwired - Jan 21, 2014) - BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU) today announced that it has entered into an Exclusive Distribution Agreement with Quip Laboratories (Quip) for the market segments of laboratory animal research and biomedical research. Since 1981, Quip has been a leader in sales distribution of cleaning and disinfection solutions to the life science marketplace.

This relationship represents a major step forward to expand our distribution of our YGIENE™ and OGIENE™ products to these important life science markets. Through Quip's team of industry experts and highly trained sales professionals we gain direct access to decision makers providing us with an opportunity to make an immediate impact with accounts and applications on the forefront of scientific research. This arrangement enables BioNeutral products to become featured within Quip Laboratories' comprehensive biosafety solutions which, in turn, will streamline the trial and purchase process among customers seeking to accelerate their processing times and reduce overall costs.

"Quip Laboratories is very pleased to add BioNeutral products to our roster of innovative biosafety product technologies for which we are renowned," said Quip Laboratories President, Tim Hidell. "Throughout our three decades of growth, our clients have come to rely on us for breakthrough products that address their facility hygiene challenges," he continued. "This exclusive partnership leverages Quip's leadership in the biosafety industry as well as BioNeutral's product excellence in product innovation and performance. We are proud of this partnership," Hidell said, "and we are confident that the addition of the BioNeutral products to our portfolio will facilitate their broad adoption across North America."

"This exclusive partnership is a major component of our market specific channel and distribution strategy. This agreement entrenches BioNeutral in the life sciences industry with one of the dominant players. Quip has a history of being on the forefront of developing and introducing new, innovative technologies to the biosafety industry," said Ray Dunning, Senior Vice President of Sales for BioNeutral. "Additionally, this gives us the ability to support Quip's experienced team and diverse customer base, while expanding their product line with a high performing sporicide/sterilant offering the unique capabilities that are in greater demand today."

About Quip Laboratories, Inc.

Based in Wilmington, DE and founded in 1981, Quip Laboratories focuses on providing sanitation solutions to Life Science and Food Processing sectors. Their state-of-the-art manufacturing facility produces proprietary chemicals that have enabled the company to achieve a leadership position in the markets served. Featuring in-house research and development, production, quality control and sales and marketing, Quip provides a "total-systems" approach to providing efficient and eco-gentle environment hygiene. Find Quip at

About BioNeutral Group, Inc.

Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. For more information on BioNeutral, including a listing of company products, leadership and background please visit

Find us on Facebook:

Follow us on Twitter:

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.

Contact Information

    Mark Lowenthal
    BioNeutral Group, Inc.